Enlarged Supervisory Board
05.11.2012 - British GPCR drug discovery specialist Heptares Therapeutics Ltd has named Roger M. Perlmutter to its Board of Directors.
Perlmutter brings in more than 30 years of experience in academic and pharmaceutical industry research. The physician began his academic career in 1979 at Massachusetts General Hospital. After working at the University of Washington's Howard Hughes Medical Institute from 1984-1997, he joined Merck&Co as VP Preclinical & Basic Research. In 2001, Perlmutter became VP of R&D at Amgen Inc., where he stayed until he retired in 2012.